John Boniface
Chief Tech/Sci/R&D Officer presso SERA PROGNOSTICS, INC.
Patrimonio netto: 1 M $ in data 31/03/2024
Posizioni attive di John Boniface
Società | Posizione | Inizio | Fine |
---|---|---|---|
SERA PROGNOSTICS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2011 | - |
Storia della carriera di John Boniface
Precedenti posizioni note di John Boniface
Società | Posizione | Inizio | Fine |
---|---|---|---|
Bioinformatics Solutions, Inc.
Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Chief Tech/Sci/R&D Officer | - | - |
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Corporate Officer/Principal | - | - |
MYRIAD GENETICS, INC. | Corporate Officer/Principal | - | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Corporate Officer/Principal | - | - |
MYREXIS, INC. | Corporate Officer/Principal | - | - |
Formazione di John Boniface
University of Massachusetts | Undergraduate Degree |
Albany Medical College | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Canada | 2 |
Posizioni
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
MYRIAD GENETICS, INC. | Health Technology |
MYREXIS, INC. | Finance |
SERA PROGNOSTICS, INC. | Health Services |
Aziende private | 3 |
---|---|
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Bioinformatics Solutions, Inc.
Bioinformatics Solutions, Inc. Packaged SoftwareTechnology Services Bioinformatics Solutions, Inc. develops and innovate PEAKS software platform. The firm products are discovery, antibody based, and PEAKS components identify and quantify proteins in very complex biological samples with LC-MS. It also focused on serving the proteomics research community. The company was founded in 2000 and is headquartered in Waterloo, Canada. | Technology Services |
- Borsa valori
- Insiders
- John Boniface
- Esperienza